Strategic partnerships ivWatch has recently partnered with Aon to quantify and model the clinical and financial impact of IV infiltration injuries, presenting a clear entry point for collaborating with risk management, insurance, and healthcare payer networks to expand adoption and create ROI-driven sales pitches.

Clinical impact ROI The company emphasizes hard cost savings and liability reduction from early detection of IV infiltrations, providing a compelling value proposition for hospital procurement, patient safety committees, and finance teams focused on total cost of care and risk mitigation.

Leadership momentum Board additions and leadership appointments in 2025 signal strategic growth and governance strength, which can be leveraged to engage health system executives and capital investment committees seeking proven governance and scalable deployment capabilities.

Recognition and credibility Awards for safety storytelling and industry recognition position ivWatch as a differentiated safety technology, offering credibility in vendor evaluations and opportunities to target health systems prioritizing patient safety initiatives and clinical outcome improvements.

Market timing The focus on IV safety addresses a widespread, underreported adverse event with significant cost impact, creating urgency for hospitals to adopt predictive sensing technology as part of patient safety programs and value-based care strategies.